Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Improving type 2 diabetes using incretin analogues is becoming increasingly plausible. Currently, tirzepatide is the most promising listed incretin analogue. Here, I briefly explain the evolution of drugs of this kind, analyze the residue discrepancies between tirzepatide and endogenous incretins, summarize some existing strategies for prolonging half-life, and present suggestions for future research, mainly involving biased functions. This review aims to present some useful information for designing a dual glucagon like peptide-1 receptor/glucose-dependent insulinotropic polypeptide receptor agonist.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“incretins, glucagon like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), have been identified.(1) GLP-1 receptor agonists are broadly applied in type 2 diabetes mellitus (T2DM) therapy.”
BackgroundDiscovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105 · cited 10×
“the second residue of exenatide is Gly rather than Ala; thus, it can circumvent the degradation of dipeptidyl peptidase-4 (DPP-4) and has a prolonged intravenous half-life of 30 min and a 2–3 h half-life after subcutaneous administration.(2) Liraglutide is designed to bind to human albumin via a C16 fatty acid and a s…”
InfluentialCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882 · cited 15×
“The mechanism remains unclear; Moon et al suggested a hypothesis that GLP-1 Thr 13 interacts with a binding pocket formed by Ile 196 , Leu 232 , and Met 233 of GLP-1R because Thr 7 -containing chimeric peptides are highly sensitive for the Ile 196 mutation; 24 but it contradicts the model constructed by Zhang et al th…”
InfluentialFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815 · cited 1×
“The dose of 5mg MAR709 was determined to be not tolerated(54) while a wide dose range of tirzepatide from 1mg to 15mg was established.(52) The discrepancy of clinical efficacy of these two drugs is due at least partially to their difference of proportion of GLP-1 and GIP activity.”
BackgroundKnudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696 · cited 2×
“15,23 Tyr 1 and Ile 7 are crucial for the selective activation of GIPR by GIP.”
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2022) · JAMA · doi:10.1001/jama.2022.0078 · Cited by 597
Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein
Zhang, Y., Sun, B., Feng, D., Hu, H., Chu, M., Qu, Q., Tarrasch, J. T., Li, S., Sun Kobilka, T., Kobilka, B. K., et al. (2017) · Nature · doi:10.1038/nature22394 · Cited by 576
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541 · cited 2×
“56 This may be the secret of the extraordinary efficacy of tirzepatide, but it is still possible that the best ratio of GLP-1 and GIP activity in a dual agonist has not been discovered.”
Frias, J. P., Bastyr, E. J., Vignati, L., Tschöp, M. H., Schmitt, C., Owen, K., Christensen, R. H., & DiMarchi, R. D. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.011 · Cited by 321
Structure-activity studies of glucagon-like peptide-1.
Adelhorst, K., Hedegaard, B. B., Knudsen, L. B., & Kirk, O. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37366-0 · Cited by 282
Targeting GLP-1 receptor trafficking to improve agonist efficacy
Jones, B., Buenaventura, T., Kanda, N., Chabosseau, P., Owen, B. M., Scott, R., Goldin, R., Angkathunyakul, N., Corrêa Jr, I. R., Bosco, D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03941-2 · Cited by 272
Knudsen, L. B., & Pridal, L. (1996) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00795-9 · Cited by 248
Hupe-Sodmann, K., McGregor, G. P., Bridenbaugh, R., Göke, R., Göke, B., Thole, H., Zimmermann, B., & Voigt, K. (1995) · Regulatory Peptides · doi:10.1016/0167-0115(95)00063-h · Cited by 224
GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
Holst, J. J., & Rosenkilde, M. M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa327 · Cited by 207 · cited 1×
“58 A GLP-1R agonist/GIPR antibody (antagonist) fused protein was reported promoting body weight loss.”
Borner, T., Geisler, C. E., Fortin, S. M., Cosgrove, R., Alsina-Fernandez, J., Dogra, M., Doebley, S., Sanchez-Navarro, M. J., Leon, R. M., Gaisinsky, J., et al. (2021) · Diabetes · doi:10.2337/db21-0459 · Cited by 202 · cited 1×
“Moreover, GIPR signaling blocks emesis and attenuates other negative side effects of GLP-1 receptor (GLP-1R) activation.(7) Tirzepatide is a unimolecular, bifunctional peptide invented by Eli Lilly and Company (Indianapolis, IN, USA), which simultaneously activates GLP-1R and GIPR.”
BackgroundThe Extracellular Surface of the GLP-1 Receptor Is a Molecular Trigger for Biased Agonism
Wootten, D., Reynolds, C. A., Smith, K. J., Mobarec, J. C., Koole, C., Savage, E. E., Pabreja, K., Simms, J., Sridhar, R., Furness, S. G. B., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.023 · Cited by 164
Semaglutide as a promising antiobesity drug
Christou, G. A., Katsiki, N., Blundell, J., Fruhbeck, G., & Kiortsis, D. N. (2019) · Obesity Reviews · doi:10.1111/obr.12839 · Cited by 159 · cited 1×
“The half-life of semaglutide after subcutaneous administration is up to 183 h.(4) GIP plays an important role in the incretin effect in healthy people.”
Search for α-helical propensity in the receptor-bound conformation of glucagon-like peptide-1
Murage, E. N., Schroeder, J. C., Beinborn, M., & Ahn, J. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.10.006 · Cited by 146
Widmann, C., Dolci, W., & Thorens, B. (1995) · Biochemical Journal · doi:10.1042/bj3100203 · Cited by 140
Full-length human GLP-1 receptor structure without orthosteric ligands
Wu, F., Yang, L., Hang, K., Laursen, M., Wu, L., Han, G. W., Ren, Q., Roed, N. K., Lin, G., Hanson, M. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14934-5 · Cited by 139
Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects
Zhang, H., Sturchler, E., Zhu, J., Nieto, A., Cistrone, P. A., Xie, J., He, L., Yea, K., Jones, T., Turn, R., et al. (2015) · Nature Communications · doi:10.1038/ncomms9918 · Cited by 137
Hinke, S. A., Gelling, R. W., Pederson, R. A., Manhart, S., Nian, C., Demuth, H.-U., & McIntosh, C. H. S. (2002) · Diabetes · doi:10.2337/diabetes.51.3.652 · Cited by 131
Nørregaard, P. K., Deryabina, M. A., Tofteng Shelton, P., Fog, J. U., Daugaard, J. R., Eriksson, P., Larsen, L. F., & Jessen, L. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13034 · Cited by 116
Maloney, A., Rosenstock, J., & Fonseca, V. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1307 · Cited by 115
Gault, V. A., O'Harte, F. P. M., Harriott, P., & Flatt, P. R. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6364 · Cited by 108
Irwin, N., McClean, P. L., O'Harte, F. P. M., Gault, V. A., Harriott, P., & Flatt, P. R. (2007) · Diabetologia · doi:10.1007/s00125-007-0692-2 · Cited by 106
Structure/Activity Characterization of Glucagon‐Like Peptide‐1
Gallwitz, B., Witt, M., Paetzold, G., Morys‐Wortmann, C., Zimmermann, B., Eckart, K., Fölsch, U. R., & Schmidt, W. E. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.1151b.x · Cited by 99
Gault, V. A., Flatt, P. R., & O'Harte, F. P. M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01361-5 · Cited by 99
Hansen, L. S., Sparre‐Ulrich, A. H., Christensen, M., Knop, F. K., Hartmann, B., Holst, J. J., & Rosenkilde, M. M. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13384 · Cited by 98
Hui, H., Zhao, X., & Perfetti, R. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.553 · Cited by 97
Novikoff, A., O'Brien, S. L., Bernecker, M., Grandl, G., Kleinert, M., Knerr, P. J., Stemmer, K., Klingenspor, M., Zeigerer, A., DiMarchi, R., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101181 · Cited by 95
Lu, S.-C., Chen, M., Atangan, L., Killion, E. A., Komorowski, R., Cheng, Y., Netirojjanakul, C., Falsey, J. R., Stolina, M., Dwyer, D., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100263 · Cited by 91 · cited 1×
“59 Nevertheless, whether a GLP-1R agonist/GIPR antagonist can improve T2DM needs more evidences.”
Hinke, S. A., Manhart, S., Pamir, N., Demuth, H.-U., Gelling, R. W., Pederson, R. A., & McIntosh, C. H. S. (2001) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(01)00181-9 · Cited by 84
Miranda, L. P., Winters, K. A., Gegg, C. V., Patel, A., Aral, J., Long, J., Zhang, J., Diamond, S., Guido, M., Stanislaus, S., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701522b · Cited by 83
Gault, V. A., Porter, D., Irwin, N., & Flatt, P. R. (2011) · Journal of Endocrinology · doi:10.1530/joe-10-0419 · Cited by 64
Doyle, M. E., Theodorakis, M. J., Holloway, H. W., Bernier, M., Greig, N. H., & Egan, J. M. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(03)00120-4 · Cited by 62
Bastin, M., & Andreelli, F. (2019) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s191438 · Cited by 62
Bhagavathula, A. S., Vidyasagar, K., & Tesfaye, W. (2021) · Pharmaceuticals · doi:10.3390/ph14100991 · Cited by 58
Gabe, M. B. N., van der Velden, W. J. C., Gadgaard, S., Smit, F. X., Hartmann, B., Bräuner‐Osborne, H., & Rosenkilde, M. M. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13289 · Cited by 55
Irwin, N., O'Harte, F. P. M., Gault, V. A., Green, B. D., Greer, B., Harriott, P., Bailey, C. J., & Flatt, P. R. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0509997 · Cited by 52
Efficient 18F‐Labeling of Synthetic Exendin‐4 Analogues for Imaging Beta Cells
Keliher, E. J., Reiner, T., Thurber, G. M., Upadhyay, R., & Weissleder, R. (2012) · ChemistryOpen · doi:10.1002/open.201200014 · Cited by 51
One-shot identification of SARS-CoV-2 S RBD escape mutants using yeast screening
Francino-Urdaniz, I. M., Steiner, P. J., Kirby, M. B., Zhao, F., Haas, C. M., Barman, S., Rhodes, E. R., Leonard, A. C., Peng, L., Sprenger, K. G., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109627 · Cited by 49
Li, Y., Wang, Y., Wei, Q., Zheng, X., Tang, L., Kong, D., & Gong, M. (2015) · Scientific Reports · doi:10.1038/srep18039 · Cited by 48
Moon, M. J., Park, S., Kim, D.-K., Cho, E. B., Hwang, J.-I., Vaudry, H., & Seong, J. Y. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00141 · Cited by 46
Portron, A., Jadidi, S., Sarkar, N., DiMarchi, R., & Schmitt, C. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13025 · Cited by 46
One-shot identification of SARS-CoV-2 S RBD escape mutants using yeast screening
Urdániz, I. M. F., Steiner, P. J., Kirby, M. B., Zhao, F.-Z., Haas, C. M., Barman, S., Rhodes, E. R., Peng, L., Sprenger, K., Jardine, J., et al. (2021) · bioRxiv · doi:10.1101/2021.03.15.435309 · Cited by 41
Bech, E. M., Martos-Maldonado, M. C., Wismann, P., Sørensen, K. K., van Witteloostuijn, S. B., Thygesen, M. B., Vrang, N., Jelsing, J., Pedersen, S. L., & Jensen, K. J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00787 · Cited by 39
Watanabe, Y., Kawai, K., Ohashi, S., Yokota, C., Suzuki, S., & Yamashita, K. (1994) · Journal of Endocrinology · doi:10.1677/joe.0.1400045 · Cited by 38
Gault, V., Flatt, P., Harriott, P., Mooney, M., Bailey, C., & O'Harte, F. (2003) · Journal of Endocrinology · doi:10.1677/joe.0.1760133 · Cited by 38
NMR and Alanine Scan Studies of Glucose-dependent Insulinotropic Polypeptide in Water
Alaña, I., Parker, J. C., Gault, V. A., Flatt, P. R., O'Harte, F. P. M., Malthouse, J. P. G., & Hewage, C. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510414200 · Cited by 37
Gabe, M. B. N., van der Velden, W. J. C., Smit, F. X., Gasbjerg, L. S., & Rosenkilde, M. M. (2020) · Peptides · doi:10.1016/j.peptides.2019.170224 · Cited by 37
Biological activity of AC3174, a peptide analog of exendin-4
Hargrove, D. M., Kendall, E. S., Reynolds, J. M., Lwin, A. N., Herich, J. P., Smith, P., Gedulin, B. R., Flanagan, S. D., Jodka, C. M., Hoyt, J. A., et al. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2006.12.021 · Cited by 35
Plisson, F., Hill, T. A., Mitchell, J. M., Hoang, H. N., de Araujo, A. D., Xu, W., Cotterell, A. J., Edmonds, D. J., Stanton, R. V., Derksen, D. R., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.10.044 · Cited by 29
De Block, C. E. M., Dirinck, E., Verhaegen, A., & Van Gaal, L. F. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14640 · Cited by 29
Bukrinski, J. T., Sønderby, P., Antunes, F., Andersen, B., Schmidt, E. G. W., Peters, G. H. J., & Harris, P. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00492 · Cited by 27
Simonsen, L., Holst, J. J., Madsen, K., & Deacon, C. F. (2013) · Regulatory Peptides · doi:10.1016/j.regpep.2012.12.012 · Cited by 26
de Menthière, C. S., Chavanieu, A., Grassy, G., Dalle, S., Salazar, G., Kervran, A., Pfeiffer, B., Renard, P., Delagrange, P., Manéchez, D., et al. (2004) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2004.02.002 · Cited by 24
Investigating GIPR (ant)agonism: A structural analysis of GIP and its receptor
Smit, F. X., van der Velden, W. J. C., Kizilkaya, H. S., Nørskov, A., Lückmann, M., Hansen, T. N., Sparre-Ulrich, A. H., Qvotrup, K., Frimurer, T. M., & Rosenkilde, M. M. (2021) · Structure · doi:10.1016/j.str.2021.04.001 · Cited by 24
Replacement of the C-terminal Trp-cage of exendin-4 with a fatty acid improves therapeutic utility
Lee, J. G., Ryu, J. H., Kim, S.-M., Park, M. Y., Kim, S.-H., Shin, Y. G., Sohn, J., Kim, H. H., Park, Z., Seong, J. Y., et al. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.03.004 · Cited by 23
Moon, M. J., Kim, H. Y., Kim, S. G., Park, J., Choi, D. S., Hwang, J., & Seong, J. Y. (2010) · Molecules and Cells · doi:10.1007/s10059-010-0100-5 · Cited by 21
In depth analysis of the N-terminal bioactive domain of gastric inhibitory polypeptide
Hinke, S. A., Manhart, S., Speck, M., Pederson, R. A., Demuth, H., & McIntosh, C. H. S. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.03.024 · Cited by 20
Liu, C., Li, C., Cai, X., Zou, Y., Mo, J., chen, B., Cai, Y., Han, T., Huang, W., Qian, H., et al. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104492 · Cited by 20
GIP: An Inconsequential Incretin or Not?
Pratley, R. E. (2010) · Diabetes Care · doi:10.2337/dc10-0704 · Cited by 19
Venneti, K. C., Malthouse, J. P. G., O'Harte, F. P. M., & Hewage, C. M. (2011) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2011.04.002 · Cited by 11
Wu, Y., Ji, T., Lv, J., & Wang, Z. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118025 · Cited by 6
GIP1–39, a novel insulinotropic peptide form and aspects on its mechanism of action
Xie, L., Lu, J., Östenson, C., Xu, T., & Chen, Z. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.04.013 · Cited by 5
Cited by
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310449 · Cited by 280
“moiety through a spacer in order to bind albumin and hence diminish renal clearance [50] (Figure 8).”
BackgroundIncretins (GLP-1 receptor agonists and dual/triple agonists) and the liver
Newsome, P. N., & Ambery, P. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.033 · Cited by 211
Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: A mini-review
Chavda, V. P., Ajabiya, J., Teli, D., Bojarska, J., & Apostolopoulos, V. (2022) · Molecules · doi:10.3390/molecules27134315 · Cited by 208
Natural products and drug discovery
Newman, D. J. (2022) · National Science Review · doi:10.1093/nsr/nwac206 · Cited by 169
Metadata
- Authors
- Wang, L.
- Affiliations
- China Pharmaceutical University (CN)
- Corresponding author
- Wang, Lijing
- ORCID
- Wang, Lijing
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2022-05
- Volume
- Volume 16
- Pages
- 1547-1559
- ISSN
- 1177-8881 (ISSN-L)
- PMC
- PMC9149770
- OpenAlex
- W4281388633
- Cited by
- 56
- References
- 67
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 15 · 2023: 8 · 2022: 4
- FWCI
- 1.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Drug Design Development and Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- tirzepatide, GIP/GLP-1 receptor agonist, GLP-1 receptor, GIP receptor, incretin analogues, type 2 diabetes, biased agonism, drug half-life extension, drug design
- MeSH terms
- Tirzepatide, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Receptors, Gastrointestinal Hormone, Receptors, G-Protein-Coupled, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.